OneCell Diagnostics is now 1Cell.Ai
OncoIndx is a first-in-class comprehensive genomic profiling solution developed by OneCell Diagnostics. It leverages next-generation sequencing (NGS) to analyze over
OncoDiscover® is a patented, DCGI-approved blood test designed to detect and monitor circulating tumor cells (CTCs) in real time. Built
Advancing Lung Cancer Diagnostics Through Innovation 1Cell.Ai was proud to join global experts at the ISLB Annual Congress 2024 to
Expanding Access to Precision Diagnostics in Asia 1Cell.Ai was proud to participate in Medlab Asia 2024, where we showcased our
Collaborating to Shape the Future of Cancer Care At the 2024 Oncology Think Tank Conclave in Delhi, 1Cell.Ai joined top
Driving Impact Through AI and Single-Cell Innovation At the world’s largest oncology meeting, 1Cell.Ai joined global leaders to present our
Patient: 40 years – Female diagnosed with Renal cell carcinoma Clinical Testing: Treatment Options: The MSH6 gene mutation is indicative
Patient: 66 years – Male diagnosed with High grade urothelial papillary carcinoma Clinical Testing: Treatment Options: In general CDKN2A deficient
Patient: 68 years – Female diagnosed with Intrahepatic Cholangiocarcinoma Clinical Testing: Treatment Options: MEK Inhibitor (Binimetinib) treatment can be used
Patient: 69 years – Male diagnosed with Adenocarcinoma-Gallbladder Clinical Testing: Treatment Options: As per the NCCN recommendations ERBB2 mutations benefit
